Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
Tempest Therapeutics, Inc. (OVAS)
|
|
Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
Revenues | | | | | | | | 100.0% |
Cost of goods sold | | | | | | | | 0.0% |
Gross profit | | | | | | | | 100.0% |
Research and development | | | | | | | | 112.5% |
General and administrative | | | | | | | | 74.4% |
Depreciation | | | | | | | | 2.2% |
EBIT | | | | | | | | -86.9% |
Pre-tax income | | | | | | | | -194.3% |
Income taxes | | | | | | | | 0.0% |
Net income | | | | | | | | -194.3% |
|